Session » Reproductive Issues In Rheumatic Disorders Poster

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2290

A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 2297

Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System

9:00AM-11:00AM: Abstract Number: 2296

Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 2295

Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data

9:00AM-11:00AM: Abstract Number: 2287

Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion

9:00AM-11:00AM: Abstract Number: 2294

Contraception Documentation Rates in Women with Rheumatic Diseases on Teratogenic Medications in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2292

Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?

9:00AM-11:00AM: Abstract Number: 2275

Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

9:00AM-11:00AM: Abstract Number: 2285

Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers

9:00AM-11:00AM: Abstract Number: 2276

Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach

9:00AM-11:00AM: Abstract Number: 2283

Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 2286

Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?

9:00AM-11:00AM: Abstract Number: 2291

Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2278

Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2277

Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists

9:00AM-11:00AM: Abstract Number: 2293

Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy

9:00AM-11:00AM: Abstract Number: 2279

Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 2288

Pregnancy Outcomes in Women Exposed to Golimumab

9:00AM-11:00AM: Abstract Number: 2289

Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells

9:00AM-11:00AM: Abstract Number: 2282

Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population

9:00AM-11:00AM: Abstract Number: 2280

Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention

9:00AM-11:00AM: Abstract Number: 2273

Risk of Serious Infections in Offspring According to TNFi Subtypes

9:00AM-11:00AM: Abstract Number: 2274

Targeted Education Improves Awareness of Reproductive Health Issues Among Women with Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 2284

The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development

9:00AM-11:00AM: Abstract Number: 2281

The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].